Camp4 Therapeutics Corporation (CAMP)
NASDAQ: CAMP · Real-Time Price · USD
4.340
+0.140 (3.33%)
At close: Jun 23, 2026, 4:00 PM EDT
4.627
+0.287 (6.61%)
After-hours: Jun 23, 2026, 7:28 PM EDT

Camp4 Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022
Period Ending
Mar '26 Dec '25 Dec '24 Dec '23 Dec '22
3.933.50.650.35-
Revenue Growth (YoY)
160.53%436.50%86.29%--
Gross Profit
3.933.50.650.35-
Selling, General & Admin
17.7517.3614.9211.6110.23
Research & Development
38.2238.238.8240.6234.77
Other Operating Expenses
-0.49---
Total Operating Expenses
55.9756.0553.7452.2345
Operating Income
-52.53-52.56-53.09-51.88-45
Interest Income
2.52.171.332.810.9
Other Non-Operating Income (Expense)
0.01-30.02-0.03-0.22-0.1
Total Non-Operating Income (Expense)
2.5-27.851.32.590.81
Pretax Income
-50.02-80.4-51.79-49.29-44.19
Net Income
-50.02-80.4-51.79-49.29-44.19
Net Income to Common
-18.33-80.4-51.79-49.29-44.19
Shares Outstanding (Basic)
4030500
Shares Outstanding (Diluted)
4030500
Shares Change (YoY)
314.15%547.76%1087.44%10.71%-
EPS (Basic)
-2.36-2.65-11.04-124.80-123.87
EPS (Diluted)
-2.36-2.65-11.04-124.80-123.87
Free Cash Flow
-26.25-29.83-46-44.83-42.57
Free Cash Flow Per Share
-0.66-0.98-9.81-113.51-119.32
Gross Margin
100.00%100.00%100.00%100.00%-
Operating Margin
-1335.18%-1502.43%-8142.33%-14822.60%-
Profit Margin
-1271.58%-2298.54%-7943.40%-14083.10%-
FCF Margin
-667.21%-852.83%-7055.67%-12809.40%-
EBITDA
-50.79-50.92-51.39-50.2-44.12
EBITDA Margin
-1291.00%-1455.57%-7882.21%-14343.10%-
EBIT
-52.53-52.56-53.09-51.88-45
EBIT Margin
-1335.18%-1502.43%-8142.33%-14822.60%-
SEC Filings: 10-K · 10-Q